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During the last decade psoralens have become increas-
ingly popular in treating psoriasis. The well-known pho-
tosensitizing action of these drugs has led to increasing 
concern regarding potential ocular complications, par-
ticularly in patients receiving prolonged psoralen ther-
apy. We have demonstrated that this drug can be found 
in lenses of rats injected (intraperitoneally) with 4-8 mg/ 
kg of 8-methoxypsoralen (8-MOP) and that its presence 
can lead to a photosensitized enhancement of lenticular 
fluorescence. Our experiments suggest one mechanism 
regarding the photosensitizing properties of 8-MOP 
within the ocular lens. Photo-addition products are gen-
erated with certain amino acid residues in the lens pro-
teins which may result in the permanent retention of 
this compound within the ocular lens. 
We have recently shown that free 8-MOP can also be 
detected in human lenses for at least 12 hr following oral 
ingestion. Since the free 8-MOP tends to diffuse out of 
the lens during this period of time (as long as photic 
stimulation is prevented) it may be possible to prevent 
these photochemical reactions if the patient avoids ex-
posure to ambient light for 12-24 hr immediately follow-
ing ingestion of the drug. It may also be possible to 
protect these patients with special glasses which are 
capable of reflecting all UV radiation (up to 400 nm) 
while completely transmitting the visible radiation (400-
750 nm). 
During the past decade a considerable amount of evidence 
has accumulated implicating ultraviolet radiation (between 
300-400 nm) as a significant factor in the generation of fluOJ'es-
cent compounds in the ocula.r lens [1-13). There is a progressive 
increase in the number and concentration of photochemically 
induced pigments in the aging lens and some of these chromo-
ph ores appear to be associated with protein cross-linking and 
the subsequent increase in insoluble lens proteins [1 ,3,8-14). 
The increased insolubilization of previously soluble lens pro-
teins and in the number and concentration of fluorescent com-
pounds in the lens are 2 well-documented aging parameters 
[11,13,15). It has also been demonstrated that ultraviolet radia-
tion above 300 nm is capable of generating cataracts in the 
mouse, rat, rabbit, primate and human lens [16-18]). The 
normal human cornea transmits almost all of the ultraviolet 
light above 300 nm, particularly in the younger individual, 
although there is a decrease in the percent of UV radiation 
transmitted as one ages [19). Thus the human ocular lens is 
constantly exposed to ambient ultraviolet radiation above 300 
nm throughout life, and it is postulated that this radiation plays 
a role in lens aging and in cataractogenesis. 
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Aside from the direct photochemical effects of ultraviolet 
radiation on the ocular lens, there is also the possibility of 
enhanced photobiologic damage by means of photosensitized 
reactions due to the accumulation of certain drugs within the 
ocular lens. Since 1947 when the psoralens were first introduced 
as a method for treating vitiligo [20] there has been sporadic 
interest as to the potential relationship between psoralens and 
ocular damage, particularly cataract formation. Several inves-
tigators have reported on the experimental production of cata-
racts in animals given high doses of psoralens and exposed to 
UV A [21-24). 
During the last decade psoralens and UV A therapy have 
become increasingly popula.r in the therapy of psoriasis 
[25,26). The photosensitizing action of these drugs has been 
correlated in vitro with the generation of cyclobutane photoad-
dition reactions with thymine in the DNA molecule [27-32). A 
similar mechanism has recently been proposed for 8-MOP 
photosensitized lens damage [33). The effect of such binding 
may be an enhanced potentiation of the photosensitizing action 
of the psoralens. That is, the 4',5'-cyclobutane monoadduct 
between 8-MOP and thymine may in tW"n act as new photosen-
sitizers at longer UV wavelengths (365 nm) resulting in DNA 
cross-linking [31]. 
It has been suggested that 8-MOP might also react photo-
chemically with proteins [34]. The site of this binding is as yet 
unknown, however, triplet excited states of several psoralens 
are effectively quenched by aromatic amino acids, most notably 
txyptophan [35], implicating these amino acids as possible 
photoreaction sites. 
It should be noted that because of the unique structure of 
the ocular lens (it is completely encapsulated and never sheds 
any of its cells throughout life), protein bound 8-MOP would 
be retained and accumulate within this organ following repeated 
therapy. In order to evaluate the potential ocular hazard of 8-
MOP therapy, we utilized phosphorescence and electron para-
magnetic resonance (EPR) spectroscopy to detect this drug in 
the lens and determine whether protein bound photoadducts 
could be generated by exposw-e to UV A radiation. 
METHODS 
Phosphorescence and EPR pectroscopy were performed on whole 
lenses (or pw-ified lens proteins) in ethylene glycol at 77°K as described 
in previous communications [36-38]. AU in vitro (excised lenses) irra-
diations were performed with monochromatic UV radiation at 360 nm 
as previously described [37]. A Model 8330-A H ewlett Packru'd cali-
brated radiant flux meter was used for irradiance measw-ements. The 
irradiance received by the samples was 500 mw/ cm2• Our ambient 
laboratory light experiments utilized ordinary fluorescent GE "day-
light" lamps (40 w) whose output in the 300-400 nm range is up to 25 
/lw/ l0 nm/ lumen. 
RESULTS AND DISCUSSION 
We have demonstrated that free 8-MOP can be detected in 
human lenses for at least 12 hr following oral ingestion of a 
single therapeutic dose (Fig 1). A similar situation pertains 
when rats are given an intraperitoneal (I.P.) injection of 4-8 
mg/ kg of 8-MOP [36,37]. If these lenses are not exposed to 
ambient light, the free 8-MOP tends to diffuse out of the lens 
within 12-24 hr (Fig 2), but exposw-e to ambient light will result 
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in a photosensitized enhancement of lenticular phosphores-
cence [37]. As shown in Fig 3, when a lens (derived 2 hr after 
the animal was given an LP. dose of 4 mg 8-MOP) is exposed to 
UV A (360 nm) for 6 hr, a new phosphorescent region can be 
demonstrated (325 nm excitation). Identical spectra have been 
obtained on lenses derived from 8-MOP treated rats which were 
exposed to ambient laboratory light for 48 hr. T his new phos-
phorescence region corresponds to similar spectra reported for 
tryptophan 8-MOP photoreaction products [39]. When such a 
lens is then examined by EPR spectroscopy, a new triplet 
species can be seen (1540 gauss) as well as the tryptophan 
triplet (1460 gauss) as shown in figures 4a and 4b. These 2 
triplets demonstrated by EPR spectra correspond to the phos-
phorescence spectra for tryptophan and the new photoproduct 
(Fig 2 and 3). Lifetime decay analyses on these triplet species 
gave values of 6.8 ± 0.2 seconds for tryptophan and 2.4 ± 0.2 
seconds for the new photoproduct. We have also demonstrated 
that photoaddition products are generated with certain amino 
acid residues (particularly tryptophan) in rat and human lens 
proteins (as well as with the pyrimidine bases of DNA [32,33], 
which could result in the permanent retention of this compound 
within the ocular lens [39]. Since we have shown that free 8-
MOP tends to diffuse out of rat lenses in vivo in the absence of 
photic stimulation [37] and 8-MOP treated human lenses main-
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FIG 1. Phosphorescence spectra (at 77°K) of a 27-yr-old lens (de-
rived from an enucleated eye 12 hr. after the patient was given 0.75Amg 
8-MOP/kg). 8-MOP phosphorescence (-- ) in lens (equivalent to 10-7 
M concentration). 8-MOP solution ·in ethylene glycol ( ..... . ). Tryp-
tophan phosphorescence (-----) . 
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FIG 2. Phosphorescence spectra of a lens derived from a rat given 8-
MOP (by oral intubation) and maintained in the dark for 24 hr. Only 
tryptophan phosphorescence (- - - - - - -) can be demonstrated. 
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FIG 3. P hosphorescence spectra of a rat lens treated with 8-MOP 
and UV A radiation. New phosphorescence (325 nm excitation) is now 
apparent (--) as well as a relatively structureless 360 nm excitation 
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F IG 4. A, EPR spectrum of an aqueous solu tion of 10-" M tryptophan 
showing typical triplet at 1460 gauss. u = 9.10 GHz. B, EPR spectra of 
same lens as shown in F ig 3. Aside from the tryptophan triplet (at 1460 
gauss) a new triplet at 1540 gauss is now present (u= 9.10 GHz). T hese 
2 triplets correspond to the triplets noted by phosphorescence spec-
troscopy for tryptophan (290 nm excitation) and the new 325 nm 
excited photoproduct as shown in Fig 3. Their respective lifetimes ar e 
6.8 sec (tryptophan) and 2.4 sec for the photoproduct. 
tained in the dark (after extraction) for 24 hr (unpublished 
data), it might be possible to prevent these photochemical 
reactions in the human if the patient avoids exposure to ambient 
light for 12- 24 hr immediately following ingestion of this drug. 
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We have suggested that one way to accomplish this is to treat 
patients as late in the afternoon as possible a nd instruct them 
to avoid exposure to ambient light for at least 12 hr following 
ingestion of the drug. 
The recent introduction of the Spectra-Shield lens and lens 
coating* may provide a good protective device for such patients 
since these lenses are capable of completely reflectin g all UV 
light (as well as LR. radiation above 750 nm) while transmitting 
visible radiation at levels higher than 80%. A similar degree of 
protection can be obtained if a coating is applied to the patient's 
own glasses. Preliminary studies on such coated lenses indicate 
that they are stable to UV radiation and are nontoxic. Studies 
are currently in progress to fUJ·ther assess these lenses and lens 
coatings with respect to theil' efficacy for patients on this form 
of t herapy as well as for individuals exposed to excessive 
amounts of UV radiation in industry. A detailed list of protec-
t ive goggles is available in the British Journal of Dermatology 
98:137, 1978. 
Since the normal ocular lens acts as a very efficient UV fliter 
[11] th e presence of 8-MOP in the retina has received little 
attention. A recent report demonstrating the presence of 8-
MOP in rat retinas [40] indicates that aphakic patients should 
be treated with particular caution when considering psoralen 
therapy. Since these individuals have lost theil' natural UV 
fllters, there is now a real hazard with respect to psoralen-
induced retinal photodamage. Particular care should be taken 
in shielding the eyes of such patients for at least 12 hI' after 8-
MOP h as been ingested. 
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